AR079428A1 - Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares - Google Patents
Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovascularesInfo
- Publication number
- AR079428A1 AR079428A1 ARP100104270A ARP100104270A AR079428A1 AR 079428 A1 AR079428 A1 AR 079428A1 AR P100104270 A ARP100104270 A AR P100104270A AR P100104270 A ARP100104270 A AR P100104270A AR 079428 A1 AR079428 A1 AR 079428A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical
- capsule according
- pharmaceutical capsule
- group
- fatty acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Composicion farmacéutica en forma de cápsula que contiene ésteres alquílicos de ácidos grasos poliinsaturados (PUFA) y principios activos farmacéuticos para el tratamiento y/o prevencion de enfermedades cardiovasculares. Reivindicacion 1: Cápsula farmacéutica que comprende una suspension de microcápsulas poliméricas que comprenden al menos un polímero y un principio activo farmacéutico seleccionado del grupo formado por los inhibidores de la enzima convertidora de angiotensina y los bloqueadores de los receptores de angiotensina, estando dichas microcápsulas suspendidas en un aceite que contiene ésteres alquílicos de ácidos grasos poliinsaturados. Reivindicacion 2: Cápsula farmacéutica segun la reivindicacion 1, donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos pertenecen a la serie omega-3. Reivindicacion 3: Cápsula farmacéutica segun la reivindicacion 2, donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos se seleccionan del grupo formado por ácido eicosapentaenoico, ácido docosahexaenoico, y/o sus mezclas. Reivindicacion 5: Cápsula farmacéutica segun la reivindicacion 4, donde el radical alquilo de dichos ésteres alquílicos se selecciona del grupo formado por etilo, metilo, propilo, butilo y/o sus mezclas. Reivindicacion 7: Cápsula farmacéutica segun la reivindicacion 1, donde dicho inhibidor de la enzima convertidora de angiotensina se selecciona del grupo formado por captopril, enalapril, enalaprilat, ramipril, quinapril, perindopril, lisinopril, benazepril, fosinopril, espirapril, trandolapril, moexipril, cilazapril, imidapril, rentiapril, temocapril, alacepril, delapril, moveltipril, zofenopril, pentopril, libenzapril, pivopril, ceronapril, indolapril, teprotida, sus sales farmacéuticamente aceptables y sus ácidos. Reivindicacion 8: Cápsula farmacéutica segun la reivindicacion 1, donde dicho bloqueador de los receptores de angiotensina II se selecciona del grupo formado por candesartán, eprosartán, irbesartán, losartán, olmesartán, telmisartán, valsartán, tasosartán, pratosartán, azilsartán, saralasina, ripisartán, elisartán, milfasartán, embusartán, fonsartán, saprisartán, zolasartán, forasartán, pomisartán, abitesartán, fimasartán, N-bencil-losartán, enoltasosartán, glicil-losartán, opomisartán, tritil-losartán, sarmesina, isoteolina y sus sales farmacéuticamente aceptables. Reivindicacion 9: Cápsula farmacéutica segun la reivindicacion 1, donde el polímero de dichas microcápsulas se selecciona del grupo formado por proteínas, poliésteres, poliacrilatos, policianoacrilatos, polisacáridos, polietilenglicol y/o sus mezclas. Reivindicacion 11: Cápsula farmacéutica segun la reivindicacion 1, donde dichas microcápsulas representan entre el 0,001% y el 80% del peso total de la cápsula. Reivindicacion 14: Cápsula farmacéutica segun la reivindicacion 1, donde la composicion de la cubierta de dicha cápsula se selecciona del grupo formado por gelatina, hidroxipropilmetilcelulosa, pululano, almidones modificados, carragenanos y/o sus mezclas. Reivindicacion 16: Cápsula farmacéutica segun la reivindicacion 1, donde dicha cápsula comprende un recubrimiento entérico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931024A ES2364011B1 (es) | 2009-11-20 | 2009-11-20 | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR079428A1 true AR079428A1 (es) | 2012-01-25 |
Family
ID=43498490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100104270A AR079428A1 (es) | 2009-11-20 | 2010-11-18 | Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2501365A2 (es) |
JP (1) | JP2013511480A (es) |
KR (1) | KR20120117986A (es) |
CN (1) | CN102711735A (es) |
AR (1) | AR079428A1 (es) |
AU (1) | AU2010321248A1 (es) |
BR (1) | BR112012011902A2 (es) |
CA (1) | CA2781434A1 (es) |
ES (1) | ES2364011B1 (es) |
IL (1) | IL219874A0 (es) |
MX (1) | MX2012005744A (es) |
RU (1) | RU2012122886A (es) |
TW (1) | TW201141469A (es) |
WO (1) | WO2011060945A2 (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2385240B1 (es) * | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
WO2013168021A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
JP2015519333A (ja) | 2012-05-07 | 2015-07-09 | セリックスビオ プライヴェート リミテッド | 神経疾患の治療のための組成物および方法 |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
CA2873096A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
CN104603097A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗多发性硬化症的组合物和方法 |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
CN104583182A (zh) | 2012-05-23 | 2015-04-29 | 塞利克斯比奥私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
KR101414873B1 (ko) * | 2012-06-28 | 2014-07-03 | 보령제약 주식회사 | 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물 |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
KR101391551B1 (ko) * | 2012-07-10 | 2014-05-02 | 보령제약 주식회사 | 심부전증 예방, 완화 및 치료용 약학 조성물 및 이를 포함하는 복합제제 |
WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
WO2014037834A2 (en) | 2012-09-08 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and lipid disorders |
US20150126568A1 (en) * | 2012-09-13 | 2015-05-07 | Mahesh Kandula | Compositions and methods for the treatment of hypertension and management of diabetic kidney disease |
CN102895205A (zh) * | 2012-11-09 | 2013-01-30 | 重庆市力扬医药开发有限公司 | 一种快速溶出的阿齐沙坦药物制剂 |
FR3002736B1 (fr) | 2013-03-04 | 2015-06-26 | Virbac | Composition orale nutritionnelle et medicamenteuse a usage veterinaire |
FR3002735B1 (fr) * | 2013-03-04 | 2015-07-03 | Virbac | Composition orale nutritionnelle et medicamenteuse a usage veterinaire |
AU2014230182B2 (en) | 2013-03-14 | 2016-12-22 | Boryung Pharmaceutical Co., Ltd. | Pharmaceutical combination drug |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
RU2577685C1 (ru) * | 2014-09-19 | 2016-03-20 | Александр Александрович Кролевец | Способ получения нанокапсул лозартана калия в альгинате натрия |
CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
ES2799309T3 (es) | 2014-09-29 | 2020-12-16 | Cellix Bio Private Ltd | Compuestos y composiciones para el tratamiento de esclerosis múltiple |
RU2605848C2 (ru) * | 2014-10-10 | 2016-12-27 | Александр Александрович Кролевец | Способ получения нанокапсул лекарственных препаратов группы цефалоспоринов в интерфероне |
CA2965449C (en) | 2014-10-27 | 2020-11-10 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
CN107428697A (zh) | 2015-01-06 | 2017-12-01 | 塞尔利克斯生物私人有限公司 | 用于治疗炎症和疼痛的组合物和方法 |
RU2596476C1 (ru) * | 2015-04-27 | 2016-09-10 | Александр Александрович Кролевец | Способ получения нанокапсул лекарственных растений, обладающих спазмолитическим действием |
JP6298435B2 (ja) * | 2015-10-28 | 2018-03-20 | 大原薬品工業株式会社 | アンジオテンシンii受容体拮抗薬を含有する口腔内崩壊錠 |
CN106074542A (zh) * | 2016-08-30 | 2016-11-09 | 佛山市弘泰药物研发有限公司 | 一种阿齐沙坦酯钾盐软胶囊的制备方法 |
KR101914051B1 (ko) * | 2018-07-13 | 2018-12-28 | (주)바이오제닉스 | 숯이 함유된 이중 캡슐 및 이의 제조방법 |
CN114617264A (zh) * | 2020-12-14 | 2022-06-14 | 深圳市前海小藻科技有限公司 | 具有高含量epa的植物胶囊制剂 |
CN116801876A (zh) * | 2020-12-28 | 2023-09-22 | 株式会社丘阿德 | 慢性肾脏病的治疗用药物组合物 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5312473B1 (es) | 1971-05-24 | 1978-05-01 | ||
PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4830853A (en) | 1986-10-20 | 1989-05-16 | Warner-Lambert Company | Drug compositions stabilized against oxidation |
US4793998A (en) | 1986-10-20 | 1988-12-27 | Warner-Lambert Company | Stabilized drug compositions |
US4743450A (en) | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
DE3739690A1 (de) | 1987-11-24 | 1989-06-08 | Hoechst Ag | Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen |
US5035896A (en) | 1988-06-15 | 1991-07-30 | Warner-Lambert Company | Water insoluble drugs coated by coacervated fish gelatin |
HU222489B1 (hu) | 1990-07-25 | 2003-07-28 | Novartis Ag. | Stabilizált gyógyszerkészítmények és eljárás az előállításukra |
CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
TW284688B (es) | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
US5447729A (en) | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
GB2290965A (en) | 1994-07-11 | 1996-01-17 | Therapicon Srl | Multiple layer capsules for drugs |
TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
WO1999062560A1 (en) | 1998-06-05 | 1999-12-09 | Warner-Lambert Company | Stabilization of compositions containing ace inhibitors using magnesium oxide |
US20040157911A1 (en) | 1999-08-31 | 2004-08-12 | Spiridon Spireas | Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof |
HU226950B1 (en) | 1999-11-03 | 2010-03-29 | Richter Gedeon Nyrt | The magnesium salt of enalapril and antihypertensive pharmaceutical composition containing it |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
CA2357982A1 (en) | 2001-09-28 | 2003-03-28 | Bernard Charles Sherman | Solid compositions comprising ramipril |
WO2003059330A1 (en) | 2002-01-15 | 2003-07-24 | Ranbaxy Laboratories Limited | Stable pharmaceutical compositions comprising ace inhibitor(s) |
ITMI20020731A1 (it) * | 2002-04-08 | 2003-10-08 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3 |
AU2004206109A1 (en) | 2003-01-21 | 2004-08-05 | Ranbaxy Laboratories Limited | Co-precipitated amorphous losartan and dosage forms comprising the same |
US20060177498A1 (en) | 2003-01-22 | 2006-08-10 | Ramaswami Bharatrajan | Solid pharmaceutical composition comprising ramipril |
US20060188568A1 (en) | 2003-10-30 | 2006-08-24 | Lupin Limited | Stable formulations of ace inhibitors and methods for preparation thereof |
WO2005070398A2 (en) | 2004-01-23 | 2005-08-04 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
WO2005079751A2 (en) | 2004-01-23 | 2005-09-01 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of candesartan cilexetil |
WO2005084648A1 (en) | 2004-02-27 | 2005-09-15 | Ranbaxy Laboratories Limited | Pharmaceutical compositions comprising candesartan cilexetil |
US20080311207A1 (en) | 2004-09-08 | 2008-12-18 | Manoj Varshney | Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis |
ES2255426B1 (es) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
EP1817007A2 (en) | 2004-11-05 | 2007-08-15 | King Pharmaceuticals Research and Development Inc. | Stabilized individually coated ramipril particles, compositions and methods |
US20060160871A1 (en) | 2004-12-07 | 2006-07-20 | Nektar Therapeutics | Stable non-crystalline formulation comprising losartan |
EP1674080A1 (en) | 2004-12-24 | 2006-06-28 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising valsartan |
WO2006081518A2 (en) | 2005-01-28 | 2006-08-03 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
CA2646131C (en) * | 2005-03-21 | 2018-09-04 | Vicus Therapeutics Spe 1, Llc | Compositions and methods for ameliorating cachexia |
GR1006875B (el) | 2005-06-30 | 2010-07-12 | "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., | Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων. |
US20070166372A1 (en) | 2006-01-19 | 2007-07-19 | Mai De Ltd. | Preparation of solid coprecipitates of amorphous valsartan |
WO2007103557A2 (en) * | 2006-03-09 | 2007-09-13 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
US20070281000A1 (en) | 2006-06-02 | 2007-12-06 | Michael Fox | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
WO2008001184A2 (en) | 2006-06-26 | 2008-01-03 | Emcure Pharmaceuticals Limited | Solid composition |
WO2008000040A1 (en) | 2006-06-30 | 2008-01-03 | Alphapharm Pty Ltd | A stabilised composition comprising ace inhibitors |
EP2049510A1 (en) | 2006-07-28 | 2009-04-22 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of candesartan cilexetil form i |
WO2008076780A2 (en) | 2006-12-14 | 2008-06-26 | Isp Investments Inc. | Amorphous valsartan and the production thereof |
EP1952806A1 (en) | 2007-02-01 | 2008-08-06 | Helm AG | Process for the preparation of adsorbates of candesartan |
EP1997479A1 (en) | 2007-05-31 | 2008-12-03 | Helm AG | Stabilized amorphous candesartan cilexetil compositions for oral administration |
JP5421126B2 (ja) * | 2008-01-10 | 2014-02-19 | 武田薬品工業株式会社 | カプセル製剤 |
-
2009
- 2009-11-20 ES ES200931024A patent/ES2364011B1/es not_active Expired - Fee Related
-
2010
- 2010-11-18 AR ARP100104270A patent/AR079428A1/es unknown
- 2010-11-19 AU AU2010321248A patent/AU2010321248A1/en not_active Abandoned
- 2010-11-19 RU RU2012122886/15A patent/RU2012122886A/ru unknown
- 2010-11-19 MX MX2012005744A patent/MX2012005744A/es not_active Application Discontinuation
- 2010-11-19 CA CA2781434A patent/CA2781434A1/en not_active Abandoned
- 2010-11-19 TW TW099139975A patent/TW201141469A/zh unknown
- 2010-11-19 JP JP2012539231A patent/JP2013511480A/ja active Pending
- 2010-11-19 EP EP10781842A patent/EP2501365A2/en not_active Withdrawn
- 2010-11-19 BR BR112012011902A patent/BR112012011902A2/pt not_active IP Right Cessation
- 2010-11-19 KR KR1020127015768A patent/KR20120117986A/ko not_active Application Discontinuation
- 2010-11-19 CN CN201080052613XA patent/CN102711735A/zh active Pending
- 2010-11-19 WO PCT/EP2010/007025 patent/WO2011060945A2/en active Application Filing
-
2012
- 2012-05-17 IL IL219874A patent/IL219874A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2012005744A (es) | 2012-12-05 |
TW201141469A (en) | 2011-12-01 |
RU2012122886A (ru) | 2013-12-27 |
CA2781434A1 (en) | 2011-05-26 |
WO2011060945A2 (en) | 2011-05-26 |
EP2501365A2 (en) | 2012-09-26 |
KR20120117986A (ko) | 2012-10-25 |
AU2010321248A1 (en) | 2012-06-07 |
ES2364011B1 (es) | 2013-01-24 |
WO2011060945A3 (en) | 2012-01-19 |
BR112012011902A2 (pt) | 2017-10-10 |
ES2364011A1 (es) | 2011-08-23 |
JP2013511480A (ja) | 2013-04-04 |
IL219874A0 (en) | 2012-07-31 |
CN102711735A (zh) | 2012-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR079428A1 (es) | Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares | |
RU2014111474A (ru) | Способы лечения сердечно-сосудистых нарушений | |
HRP20110969T4 (hr) | Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije | |
PE20020229A1 (es) | COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE | |
CY1106813T1 (el) | Χρηση αναστολεων του συστηματος ρενινης-αγγειοτενσινης | |
AU2005249514B2 (en) | Compositions comprising nebivolol | |
NZ701609A (en) | Liquid formulation comprising propylene glycol and an inodilator | |
BRPI0507887A (pt) | comprimido de múltiplas camadas | |
JP2013506684A5 (es) | ||
NI201000159A (es) | Cápsula para la prevención de enfermedades cardiovasculares. | |
UA103844C2 (ru) | Фармацевтический состав, который содержит в матрице, которая подвергается эрозии, один или более эфиров фумаровой кислоты | |
CR20110224A (es) | Pirazolopirimidina inhibidor jak compuestos y metodos | |
JP2014515401A5 (es) | ||
JP2014528903A5 (es) | ||
WO2011126903A3 (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
PE20080661A1 (es) | COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa | |
RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
AR063155A1 (es) | Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos | |
AU2007205298A1 (en) | Drug combinations | |
AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
HRP20171209T1 (hr) | Farmaceutski pripravak za liječenje upalnih bolesti posredovanih putem mcp-1 | |
PE20120647A1 (es) | Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular | |
RU2016126852A (ru) | Комбинированный фармацевтический препарат, содержащий блокатор рецептора ангиотензина-II и ингибитор ГМГ-КоА редуктазы | |
ES2530847T3 (es) | Nuevas estrategias terapéuticas para tratar afecciones neuroinflamatorias | |
AR068385A1 (es) | Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |